Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: A multicenter study of the Arbeitsgemeinschaft Internistische Onkologie

Oncology (Switzerland)

Volumn 84, Issue 5, 2013, Pages 284-289

  Knoedler, M ^a   Gauler, T C ^b   Gruenwald, V ^c   Matzdorff, A ^d   Schroeder, M ^e   Dietz, A ^f   Jordan, W O ^g   Arnold, D ^h   Hennemann, B ⁱ   Hofele, C ^j   Weissinger, F ^k   Eberhardt, W ^b   Keilholz, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d CaritasKlinikum St Theresia Saarbrücken Klinik   (Germany)

^e Hospital St Johannes   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g Department of Oncology   (Germany)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁱ UNIVERSITY OF REGENSBURG   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

Cetuximab; Disease control rate; Docetaxel; Platinum sensitivity; Squamous cell carcinoma of the head and neck

Indexed keywords

CETUXIMAB; DOCETAXEL; PLATINUM;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CAUSE OF DEATH; COHORT ANALYSIS; DISEASE CONTROL; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HEART DISEASE; HUMAN; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT HISTORY OF THERAPY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SKIN MANIFESTATION; SUDDEN DEATH; THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLEEDING;

EID: 84874285876     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000345453     Document Type: Article

References (18)

1. León X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF, Amellal N, Bessa EH, Bourhis J: A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17: 418-424.
2. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-1318.
3. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-311.
4. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1: 511-529.
5. Kang X, Patel D, Ng S, Melchoir M, Ludwig D, Hicklin D: High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol 2007; 25(suppl): 128.
6. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-1280.
7. Zhang W, Gordon M, Schultheis AM, et al: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-3718.
8. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
9. Vermorken JB, Trigo J, Hitt R, et al: Openlabel, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
10. Baselga J, Trigo JM, Bourhis J, et al: Phase ll multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinumbased chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
11. Herbst RS, Arquette M, Shin DM, et al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587.
12. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J: Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008; 112: 2710-2719.
13. Hitt R, Amador ML, Quintela-Fandino M, Jimeno A, del Val O, Hernando S, et al: Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 2006; 106: 106-111.
14. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al: Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004; 40: 2071-2076.
15. Klinghammer K, Knödler M, Schmittel A, Budach V, Keilholz U, Tinhofer I: Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximabdocetaxel treatment. Clin Cancer Res 2010; 16: 304-310.
16. Tinhofer I, Klinghammer K, Weichert W, Knödler M, Stenzinger A, Gauler T, Budach V, Keilholz U: Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2011; 17: 5197-5204.
17. Cho BC, Keum KC, Shin SJ, Choi HJ, Lee YJ, KIM SH, Choi EC, Kim JH: Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2009; 65: 27-32.
18. Specenier P, Rasschaert M, Vroman P, Van den Brande J, Dyck J, Schrijvers D, Huizing MT, Vermorken JB: Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol Epub 2011; 34: 472-427.